 we report strong results for the fourth quarter of fiscal year 2022 with revenue of $1.85 billion, up 17.5% core and 11.4% on a reported basis. Earnings per share of $1.53 were up 26% on a core basis and 20% on a reported basis.    
 our performance was again broad-based as all end markets and regions grew double digits in the quarter.    on a geographic basis, we saw 44% growth in our largest market pharma, driven by underlying demand across multiple end markets and our continued ability to quickly recover deferred revenue from the Shanghai COVID related shutdown in the second quarter.    
 we also saw double-digit growth in the food market led by China as our results continue to benefit from the recovery of revenue delays due to the COVID-related shutdowns in Q2.    
 our strong top line performance helped deliver fourth quarter operating margins of 29.1%, up 260 basis points from last year. And we have very good visibility into the first half of this year.    
 the full year revenue of $6.9 billion to $7 billion delivered core revenue growth of 12% to 15% and